The therapies using various antibodies or kinase inhibitors inhibit the CCL2/CCR2-, CXCL12/CXCR4-t, or CSF-1/CSF-1R-dependent monocyte/macrophage recruitment into the tumor. This evidence concerns the gene CCL2 and neoplasm.